Moderna Inc. (NASDAQ:MRNA)

The financial data reveals significant fluctuations in key performance indicators over the analyzed periods. The share price exhibits a notable upward trajectory from March 2019 through February 2021, reaching a peak in early 2021 and early 2022, followed by a gradual decline through February 2024.

Share Price

The share price increased substantially from $19.97 in March 2019 to $154.81 by February 2021, indicating robust market confidence or positive company developments during this period. After reaching this peak, it experienced a slight reduction to $151.33 in February 2022 and continued to decline to $96.46 by February 2024, signaling a decrease in market valuation over the last two years.

Operating Profit per Share

Operating profit per share was consistently negative from 2019 through early 2021, worsening from -$1.26 to -$1.91. In February 2022, there was a remarkable reversal, with operating profit per share jumping to $33, which subsequently declined to $24.38 in February 2023 and further turned negative to -$11.09 by February 2024. This sharp swing between profit and loss suggests volatility in operational performance or possibly extraordinary items influencing the results.

Price to Operating Profit (P/OP) Ratio

Data for the P/OP ratio is limited to the years 2022 and 2023, recorded as 4.59 and 5.71 respectively. The increase suggests that the stock price relative to operating profit increased in 2023, which may indicate market optimism despite a decreasing operating profit per share that year.

Overall, the trends suggest that while the company achieved substantial improvements in operating profitability in 2022 and early 2023, this performance was not sustained, as reflected in the negative operating profit in 2024 and declining share price. The limited and somewhat inconsistent data on valuation multiples alongside the volatility in profit per share highlight a period of financial instability or transitional phases within the company.